HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coty’s FY 2023 Will Be ‘Year Of Skin Care’; Reinstated ‘Powerhouse’ Says Growth Engines Are Fired

Executive Summary

Doubts about Coty’s “viability” have melted away with the return to growth of its Consumer Beauty division and momentum in its burgeoning skin-care and prestige cosmetics businesses. Coty now aims to beat the market with 6% to 8% compound annual revenue growth from fiscal 2022 through 2025.

You may also be interested in...

Coty’s First Refillable Fragrance Among 2022 Sustainability Highlights

Chloé Rose Naturelle Intense, Coty’s first refillable fragrance, makes its 2022 sustainability report along with green science to replace D5 silicone and the company’s partnership with LanzaTech NZ to create fragrances using ethanol made from captured carbon emissions.

Coty ‘Advantaged’ In FY 2023 With Consumer Biz Momentum, Unflagging Luxury Fragrance Demand

Coty leadership says it has not seen any slowdown in fragrance “premiumization” trends, which bodes well for its booming Prestige business. Strong momentum in Consumer Beauty and a robust innovation pipeline across both divisions have the firm targeting 6%-8% like-for-like growth in fiscal 2023.

Skin-Care Innovation Steals The Show In US Indy Pharmacies – Hamacher Resource Group

Beauty items – mostly skin care – accounted for 961, or 43.2%, of 2,227 new products tracked by HRG in 20,000 independent pharmacies in the US last year. Of new beauty products, 36, or 3.75%, received HRG Stars, awarded to products the firm deems as having greatest prospects for success.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts